PROCEPT BioRobotics Corporation

PROCEPT BioRobotics Corporation is a surgical robotics company focused on developing transformative solutions in urology. The company designs, manufactures, and sells the AquaBeam Robotic System, an image-guided surgical robotic system used for minimally invasive urologic surgery, primarily to treat benign prostatic hyperplasia (BPH). Additionally, it offers the HYDROS Robotic System, which provides Aquablation therapy—an image-guided robotic therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics operates in the United States and globally, aiming to improve outcomes for patients with urological conditions through advanced robotic technology.

PROCEPT BioRobotics Corporation is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol PRCT. The company trades in U.S. dollars (USD), as it is headquartered in the United States. Being listed on a major U.S. exchange provides liquidity and visibility to investors worldwide.

PROCEPT BioRobotics Corporation operates in the Healthcare sector, specifically within the Medical Devices industry. The company focuses on developing surgical robotic systems for urological procedures, making it a key player in the medical device space. Its products, such as the AquaBeam and HYDROS Robotic Systems, are designed for minimally invasive surgeries, aligning with the broader trend toward robotic-assisted surgery in healthcare.

PROCEPT BioRobotics Corporation is headquartered in San Jose, California, United States. The company serves both the domestic U.S. market and global markets, as indicated by its operations in the United States and internationally. Its robotic systems are used by urologists worldwide to treat benign prostatic hyperplasia (BPH) and related conditions, leveraging its San Jose base for research, development, and manufacturing.